Clinical trial
A Phase II Study of CC-5013 in Myelofibrosis
NCT00087672 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00087672 |
|---|---|
| Title | A Phase II Study of CC-5013 in Myelofibrosis |
| Official title | Phase II Study of CC-5013 in Myelofibrosis |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelofibrosis |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 41 |
| Start date | Jul 1, 2004 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Jul 14, 2004 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: